What is Olema Pharmaceuticals, Inc.'s (OLMA) StockRank?

MoatMap's StockRank for Olema Pharmaceuticals, Inc. (OLMA) is 9/100, with a Strong Sell signal. This is a composite score combining Quality (40), Value (39), and Momentum (13) factor ranks across MoatMap's 19,000+ stock universe.

Does Olema Pharmaceuticals, Inc. have an economic moat?

Olema Pharmaceuticals, Inc. (OLMA) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Olema Pharmaceuticals, Inc. a buy, hold, or sell?

MoatMap's current signal for Olema Pharmaceuticals, Inc. (OLMA) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Olema Pharmaceuticals, Inc. in?

Olema Pharmaceuticals, Inc. (OLMA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

OLMA

STRONG SELLREMOVE

Olema Pharmaceuticals, Inc. · Healthcare · United States · $1.1B · Avg Vol: $13M/d

StockRank

P/E (TTM)

—

ROE

-42.9%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on endocrine-sensitive cancers. It is a pre-revenue R&D vehicle with high cash burn and binary clinical trial risk, failing our Terry Smith and Warren Buffett quality and cash flow criteria.

COMPANY DESCRIPTION

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel targeted therapies for women's cancers. Its competitive edge derives from a focused pipeline of proprietary small molecule candidates, particularly in endocrine-sensitive tumor biology, addressing significant unmet medical needs. Olema is a high-risk, high-reward biopharma player aiming to deliver differentiated therapeutic options within the oncology landscape.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0	0	0	0	—
EPS	-1.80	-2.62	-2.14	-2.20	—	—
Shares	—	40M	55M	74M	81M	+102.0%
Debt	—	3M	2M	1M	4M	17.8%
Equity	—	198M	254M	409M	479M	34.3%
Op CF	—	-82M	-84M	-104M	-147M	—
Inv CF	—	91M	-5M	-94M	-156M	—
Fin CF	—	476,000	133M	269M	211M	—

PRICE (1M)-32.5%

SMA 50SMA 200

$9.88

RSI (14)

20.0

52W High

$36.26

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-37.1%18.7

ROE

-42.9%19.8

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-14.8%22.6

Piotroski

—28.8

Int. Cover

—N/A

D/E Ratio

0.01x89.7

Current Ratio

10.88x88.2

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.9x66.4

P/FCF

—N/A

P/B

1.7x61.9

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

27%4.5

RS 6M

-77%12.2

SMA 50/200

0.82x15.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-22%13.9

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.1B

P/E (Forward)

-4.0x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OLMA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
OLMA	Olema Pharmaceuticals, Inc.(you)	$1.1B	9	STRONG SELL
AKTS	Aktis Oncology, Inc.	$1.1B	9	STRONG SELL
EYPT	EyePoint, Inc.	$1.1B	8	STRONG SELL
AVLN	Avalyn Pharma Inc.	$1.3B	8	STRONG SELL
SPRY	ARS Pharmaceuticals, Inc.	$933M	10	STRONG SELL
ZBIO	Zenas BioPharma, Inc.	$1.2B	4	STRONG SELL
COAG	Hemab Therapeutics Holdings, Inc.	$1.3B	12	STRONG SELL
MAZE	Maze Therapeutics, Inc.	$1.5B	6	STRONG SELL
SANA	Sana Biotechnology, Inc.	$871M	4	STRONG SELL
RXRX	Recursion Pharmaceuticals, Inc.	$1.8B	9	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Olema Pharmaceuticals, Inc. (OLMA) — Stock Score Summary

Olema Pharmaceuticals, Inc. (OLMA) has a MoatMap StockRank of 9/100 based on Quality (40/100), Value (39/100), and Momentum (13/100) factor scores. The current signal is STRONG SELL. Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on endocrine-sensitive cancers. It is a pre-revenue R&D vehicle with high cash burn and binary clinical trial risk, failing our Terry Smith and Warren Buffett quality and cash flow criteria.

Key Financial Metrics

Price	$9.88
Market Cap	$1.1B
P/E (Forward)	-3.98
Price/Book	1.68
Return on Equity	-42.9%
Return on Invested Capital	-37.1%
Debt/Equity	0.82
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-79M

Olema Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Olema Pharmaceuticals, Inc.’s (OLMA) StockRank?: MoatMap’s StockRank for Olema Pharmaceuticals, Inc. (OLMA) is 9/100, with a Strong Sell signal. It is a composite of Quality (40), Value (39), and Momentum (13) factor ranks across MoatMap’s 19,000+ stock universe.
Does Olema Pharmaceuticals, Inc. have an economic moat?: Olema Pharmaceuticals, Inc. (OLMA) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Olema Pharmaceuticals, Inc. a buy, hold, or sell?: MoatMap’s current signal for Olema Pharmaceuticals, Inc. (OLMA) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Olema Pharmaceuticals, Inc. in?: Olema Pharmaceuticals, Inc. (OLMA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).